ICAM1 and neoplasm: As demonstrated in Figure S26 (Supporting Information), the maturation rate of DCs in tumor‐infiltrating lymph nodes was also obviously increased by combination therapy with ICAM‐1–Dxd and B7‐H3‐CD3.